BMRN: 拜玛林制药
今日BMRN汇率已更改-2.18%。当日,交易品种以低点54.91和高点57.00进行交易。
关注拜玛林制药动态。实时报价将帮助您快速应对市场变化。通过在不同的时间周期之间切换,您可以按分钟、小时、天、周和月监控汇率趋势和动态。使用这些信息来预测市场变化并做出明智的交易决策。
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
BMRN新闻
- Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122
- 3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside - TipRanks.com
- Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target
- BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
- The "Calendar Trick" for Huge Biotech Gains - And 3 Stocks I'm Watching
- Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
- BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis...
- FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
- BioMarin Pharmaceutical预计第三季度购入IPR&D费用税前支出为2.83亿美元;预计第三季度对GAAP和非GAAP摊薄每股收益造成1.5美元的不利影响;预计Alesta收购将在2026财年带来总计3.2亿美元的税前支出;预计2026财年对GAAP和非GAAP摊薄每股收益造成1.55美元的不利影响
- BioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55...
- BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified
- BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed
- uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE)
- Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine (NYSE:NVO)
- Tracking John Paulson’s Paulson & Company Portfolio: Q2 2026 Update (OTCMKTS:FNMA)
- BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN)
- FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
- BioMarin Stops Voxzogo Development for Noonan Syndrome
常见问题解答
BMRN股票今天的价格是多少?
拜玛林制药股票今天的定价为55.21。它在54.91 - 57.00范围内交易,昨天的收盘价为56.44,交易量达到4868。BMRN的实时价格图表显示了这些更新。
拜玛林制药股票是否支付股息?
拜玛林制药目前的价值为55.21。股息政策取决于公司,而投资者也会关注4.11%和USD。实时查看图表以跟踪BMRN走势。
如何购买BMRN股票?
您可以以55.21的当前价格购买拜玛林制药股票。订单通常设置在55.21或55.51附近,而4868和-2.11%显示市场活动。立即关注BMRN的实时图表更新。
如何投资BMRN股票?
投资拜玛林制药需要考虑年度范围49.26 - 70.98和当前价格55.21。许多人在以55.21或55.51下订单之前,会比较-7.69%和。实时查看BMRN价格图表,了解每日变化。
拜玛林制药股票的最高价格是多少?
在过去一年中,拜玛林制药的最高价格是70.98。在49.26 - 70.98内,该股波动显著,与相比有助于发现阻力位。使用实时图表跟踪拜玛林制药的绩效。
拜玛林制药股票的最低价格是多少?
拜玛林制药(BMRN)的最低价格为49.26。将其与当前的55.21和49.26 - 70.98进行比较,可以发现潜在的长期切入点。观看BMRN在图表上的实时走势以获取更多详细信息。
BMRN股票是什么时候拆分的?
拜玛林制药历史上曾经历过股票拆分。这些变化在公司行动后的、56.44和4.11%中可见。
- 前一天收盘价
- 56.44
- 开盘价
- 56.40
- 卖价
- 55.21
- 买价
- 55.51
- 最低价
- 54.91
- 最高价
- 57.00
- 交易量
- 4.868 K
- 日变化
- -2.18%
- 月变化
- -7.69%
- 6个月变化
- 2.41%
- 年变化
- 4.11%
- 实际值
- -3.060 M
- 预测值
- -4.804 M
- 前值
- -8.557 M
- 实际值
- 0.987 M
- 预测值
- -0.153 M
- 前值
- 1.862 M
- 实际值
- 预测值
- 前值
- 5.420%